65,437 trials
Alagille Syndrome
Primary: Change From MRX Baseline to Week 48 in Fasting sBA Levels — 261.96; 128.32 μmol/L — p=0.0012
Chronic Kidney Disease · Anemia
Primary: Primary Safety Outcome Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading…
Prostate Cancer
Primary: Progression-free Survival (PFS) — 5.1; 17.1; 11.9 percentage change of PSA
Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic
Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305
Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) — 35.2; 51.9 Percentage of participants
Occupational Exposure to Radiation
Primary: Percentage Change — 79.7; 71.9 percentage change
Leukemia, Myeloid, Acute
Primary: Objective Response (OR) — 38; 123 Participants — p=0.0024
Oral Mucositis
Primary: Patients Achieving Less Than or Equal to "2" RTOG Score At Visit 9 — 7 Participants
Atopic Dermatitis
Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 120; 131; 47 Participants
Obesity, Visceral · Cardiovascular Diseases · Fat Disorder
Primary: Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI — 12.49; 1.63 percentage of reduction in VAT
Rhinosinusitis
Primary: Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Full Analysis Set — -4.8213; -4.7394; -4.7758; -5.0180 Score on a scale
Diffuse Large B-cell Lymphoma · de Novo DLBCL · DLBCL Transformed From Indolent Lymphoma
Primary: Progression Free Survival (PFS) — 7.3; 6.3 Months
COVID
Primary: Number of Monitored Versus Non-Monitored In-patient Admission — 8; 9 Participants
Dermatitis
Primary: Percentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16 — 11.8; 24.6; 21.7 percentage of…
Cardiorenal Syndrome (CRS)
Primary: Change in Glomerular Filtration Rate — -5; 1.00 ml/min/1.73 m2 — p=0.26